to medical schools should include measures to detect vulnerability, and the curriculum should embody programmes which will help the student to cope with later professional stresses. Faculty advisors, tutors, and organised peer groups should be aware of their duty to recognise and intervene at an early stage rather than to wait for the GMC to take action when problems may be ineradicably established.

ISAAC SAKINOFSKY

Institute of Psychiatry,
London SE5 8AF

¹ Sakinofsky I. Suicide in doctors and wives of doctors. *Can Fam Physician* 1980;26:837-47.

² Office of Population Censuses and Surveys, England and Wales.

Beta-blockers in the treatment of myocardial infarction

SIR,—Professor Geoffrey Rose in his letter (19 April, p 1099) rightly drew attention to the need to give confidence limits in “negative” trials such as that recently reported with beta-blockers in the secondary prevention of myocardial infarction (29 March, p 885), and Dr N S Baber and Mr J A Lewis (5 July, p 59) have performed a useful service in drawing further attention to this point. They would have done better, however, to have quoted the references and omitted the names of the beta-blockers, since no comparative conclusions can possibly be drawn from the data. Their illustrative examples tend to confuse rather than clarify the situation; since their list is incomplete, it mixes studies of entirely different design and duration, and the results given arise from different types of analysis.

JØRGEN SELDRUP
DENIS BURLEY

Ciba-Geigy Pharmaceuticals Division,
Horsham, W Sussex RH12 4AB

* * * The omission of the full reference list from the letter by Dr Baber and Mr Lewis was an editorial suggestion, made regretfully to save space. The authors do, however, say in their letter that the references will be supplied on request.—ED, *BMJ*.

Hypertensive response to labetalol in phaeochromocytoma

SIR,—Dr G Reach and others (31 May, p 1300), reporting the effects of labetalol in three patients with phaeochromocytoma, conclude that the drug “could be useful in the preoperative management of patients with phaeochromocytoma provided the blood pressure was carefully monitored.” Careful blood pressure recording is required since a paradoxical rise in blood pressure has been described in two patients with phaeochromocytoma following the oral administration of labetalol.^{1,2} We have learnt caution with this drug by experiencing a similar case.

A 46-year-old man, who was admitted (day 1) with a supine blood pressure of 150/100 mm Hg rising to 260/150 mm Hg on standing, was shown preoperatively to have a phaeochromocytoma (24-h urinary conjugated metanephrine excretion 130 μ mol; normal < 3 μ mol) that was subsequently confirmed at laparotomy. Supine blood pressure readings over the first four days of admission ranged from 110/70 mm Hg to 150/100 mm Hg with the exception of an isolated reading of 220/140 mm Hg. Oral labetalol was commenced on day 5 in a dose of 200 mg 8 hourly (600 mg daily) resulting in sustained hypertension

(210/150 mm Hg), which was not abolished by increasing the dose of labetalol to 400 mg 8 hourly (1200 mg daily) on day 6 (280/160 mm Hg). Satisfactory blood pressure control was achieved by withdrawal of labetalol and the oral administration of phenoxybenzamine 10 mg 6 hourly (40 mg daily) from day 7 onwards (110/80 mm Hg). In addition propranolol was commenced from day 9 with no adverse effect on blood pressure control (120/80 mm Hg).

Hypertension in phaeochromocytoma may be aggravated by the administration of a β -adrenoreceptor blocker before adequate α -adrenoreceptor blockade is established.³ While labetalol has both α - and β -adrenoreceptor blocking actions it has predominantly β -adrenoreceptor blocking activity.⁴ Thus the administration of this drug may provoke a paradoxical rise in blood pressure in patients with phaeochromocytoma, particularly if the tumour is secreting adrenaline as its predominant catecholamine.¹ Labetalol should therefore be used with caution in patients with phaeochromocytoma and may have no advantage over conventional preparations with α -adrenoreceptor blockade followed by additional β -adrenoreceptor blockade.

COLIN M FEEK
PHILIP M EARNSHAW

Western General Hospital,
Edinburgh EH4 2XU

¹ Rosei EA, Brown JJ, Lever AF, et al. *Br J Clin Pharmacol (Suppl)* 1976;3:809-15.

² Briggs RSJ, Birtwell AJ, Pohl JEF. *Lancet* 1978;ii:1045-6.

³ Ross EJ, Prichard BNC, Kaufman L, Robertson AIG, Harris BJ. *Br Med J* 1967;i:191-8.

⁴ Brittain RJ, Levey GP. *Br J Clin Pharmacol (Suppl)* 1976;3:681-94.

Asthma and enkephalin

SIR,—Dr R D G Leslie and others (5 January, p 16) reported five patients with asthma induced by chlorpropamide alcohol (CPA). This was partially blocked in one patient by a high dose of naloxone but in another there was no definite effect. In the former patient the enkephalin analogue DAMME (250 μ g) produced tightness of the chest, breathlessness, and a fall in forced expiratory volume in one second (FEV₁), which had largely resolved by 20 minutes. They did not attempt to block this effect with naloxone. The one asthmatic patient tested experienced no change in FEV₁ with CPA or DAMME. They concluded that CPA asthma is mediated by enkephalins.

We have studied minute ventilation, FEV₁, and forced vital capacity (FVC) in six normal (non-asthmatic) subjects infused with 250 μ g of DAMME. No change in FEV₁ or FVC was recorded in any subject. In one subject hyperventilation occurred in association with a feeling of oppression in the chest, breathlessness, and anxiety (fig). Hyperventilation may precipitate an asthmatic attack¹ and it is possible that DAMME-induced hyperventilation may be responsible for the fall in FEV₁ in the asthmatic patient of Dr Leslie and his colleagues. Enkephalin-induced asthma may therefore be no more than a non-specific consequence of anxiety and hyperventilation.

A feeling of oppression in the chest lasting 20-30 minutes in about 20% of subjects given DAMME 250 μ g has previously been reported.^{2,3} The facial flushing, analgesia, and hormonal effects which occur in nearly all subjects last about two hours. The time course of the fall in FEV₁ in the asthmatic patient reported therefore approximates better

Hyperventilation in a normal subject given the enkephalin analogue DAMME.

Conversion: SI to traditional units PACO₂:—1 kPa=7.5 mm Hg.

to that of the feeling of chest oppression, anxiety, and hyperventilation. The case for CPA-induced asthma mediated by enkephalin-like substances is thus not proved. Nevertheless care should be exercised in giving DAMME to asthmatic subjects; but our initial results suggest that it is safe in normal subjects.

R J A BUTLAND
J PANG
DUNCAN GEDDES

Brompton Hospital,
London SW3 6HP

¹ McFadden ER, Ingram RH. *N Engl J Med* 1979;301:763-9.

² Krebs E, Roubicek J. *Pharmacopsychiat* 1979;12:86-93.

³ Graffenried B, Dol Pozo E, Roubicek J, et al. *Nature* 1978;272:729-30.

Effect of plasma exchange in rhesus immunisation

SIR,—Regarding the article by Mr G R Barclay and others (28 June, p 1569) on the apparent adverse effect of plasma exchange on anti-D production in rhesus immunisation, we do feel that their conclusions are unduly pessimistic. We have treated 18 similar cases with a 64% success rate (report on 14 in press).

It has been shown in animal experiments by Branda and his co-workers¹ that plasma exchange following secondary immunisation results in a permanent lowering of the antibody level. However, in a recently published article Branda² now states that when antigen is continuously present only a temporary lowering of antibody can be achieved, with a prompt return to high levels. This finding is significant with regard to the case in question.

The circumstances outlined by Mr Barclay and colleagues would strongly suggest that their patient was being regularly subjected to the Rh antigen and therefore the immunological response was “switched on.” The Rh-positive antigen could well have got into the mother’s circulation in the replacement plasma, as a result of the amniocentesis, or during intra-uterine transfusion.